Previous Article | Next Article 
Journal of Clinical Microbiology, February 2007, p. 607-609, Vol. 45, No. 2
0095-1137/07/$08.00+0 doi:10.1128/JCM.02099-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Usefulness of PCR-Restriction Fragment Length Polymorphism Typing of the Coagulase Gene To Discriminate Arbekacin-Resistant Methicillin-Resistant Staphylococcus aureus Strains
Keiko Ishino,1*
Naofumi Tsuchizaki,1,2
Jun Ishikawa,1 and
Kunimoto Hotta1
Department of Bioactive Molecules, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan,1
Japan Microbiological Clinic, Co., Ltd., 5-17-1, Okada, Atsugi, Kanagawa 243-0021, Japan2
Received 12 October 2006/
Accepted 5 December 2006

ABSTRACT
We compared the results of two typing methods for 678 strains
of methicillin-resistant
Staphylococcus aureus and methicillin-susceptible
S. aureus. PCR-restriction fragment length polymorphism typing
of the coagulase gene was a more reliable method than coagulase
serotyping from the viewpoint of arbekacin resistance.

TEXT
Molecular typing plays an important role in epidemiological
studies of nosocomial infection, such as methicillin-resistant
Staphylococcus aureus (MRSA) infection. Pulsed-field gel electrophoresis
and multilocus sequence typing are considered the most discriminatory
and reliable methods of typing, although they are technically
complex, time consuming, and expensive. Coagulase serotyping
is widely used in Japan in addition to conventional and genetic
methods for distinguishing
S. aureus strains. On the other hand,
it has been reported that PCR-restriction fragment length polymorphism
(RFLP) typing of the coagulase gene (
coa) can be used to discriminate
S. aureus strains on the basis of sequence variation within
the 3' end coding region of the gene (
1,
2,
8). Arbekacin is
effective, even in gentamicin-resistant MRSA strains, and has
been used extensively in Japan since its approval as an anti-MRSA
agent in 1990 (
9,
10). We have studied arbekacin resistance
in MRSA and recently reported the Japanese trend of arbekacin-resistant
MRSA strains in the last two decades by using
coa-RFLP typing
(
10). The results showed that arbekacin-resistant MRSA strains
were distributed over only a few
coa-RFLP types and remained
at a low level. In this study, we assessed the clinical usefulness
of
coa-RFLP typing, especially from the viewpoint of arbekacin
resistance, by comparing coagulase serotyping in both clinically
isolated MRSA and clinically isolated methicillin-susceptible
S. aureus (MSSA) in Japan.
Coagulase serotyping was performed with a coagulase-typing reagent kit (Denka Seiken Co. Ltd., Tokyo, Japan) according to the manufacturer's instructions. Based on the results, a total of 678 isolates, including 206 MSSA and 472 MRSA strains from unrelated clinical sources in Japan between 1979 and 2000 (4, 6, 7), were classified into nine serotypes, I to VIII and "other" (Table 1). MRSA strains were divided into serotypes I, II, III, IV, and VII, and most (82%) of the MRSA strains belonged to serotype II. A similar trend was previously observed in MRSA isolated in Japan (3). The serotype distribution of MSSA strains differed from that of MRSA strains. MSSA strains contained all serotypes. However, the majority of the MSSA strains were classified into serotypes II (28%) and VII (35%).
We next carried out
coa-RFLP typing according to the method
of Hookey et al., with some modifications (
2).
coa gene fragments
were amplified from colonies grown on agar plates with the primers
coaF (ATAGAGATGCTGGTACAGG) and coaR (GCTTCCGATTGTTCGATGC). As
shown in Fig.
1A, PCR products of eight sizes were obtained
from 678 isolates and named XS, SS, S, M, L, LL, XL, and XXL
according to their sizes. The sizes of the products ranged from
350 to 917 bp in increments of 81 bp, reflecting the number
of 81-bp repeat units contained in the
coa gene. After digestion
with AluI, 31
coa-RFLP types were detected and numbered to allow
them to be distinguished from each other (Fig.
1B). The majority
(77%) of MRSA strains belonged to type L21, indicating the spread
of a specific type of MRSA in Japan. In contrast, there was
no such tendency in MSSA. This result was in agreement with
the results of serotyping.
A comparison of the results of the two typing methods may illuminate
the advantages of
coa-RFLP typing from the viewpoint of arbekacin
resistance. Serotype II contains 11
coa-RFLP types, including
type L31. Previously, we reported strain PRC104 as a highly
arbekacin-resistant strain (128 µg/ml) (
5). Although the
typing data for this strain were not incorporated in Table
1 because of its history of isolation, the strain belongs to type
L31 (unpublished data). This implies that this important
coa-RFLP
type cannot be recognized by coagulase serotyping alone. Types
M22 and M31 are also important due to their high incidence of
arbekacin-resistant strains (
10). The
coa-RFLP typing clearly
distinguished type M22 or M31 isolates from other strains belonging
to serotype VII or III, respectively. Thus, our results demonstrated
that
coa-RFLP typing has higher discriminatory power than coagulase
serotyping and may be useful for discriminating groups that
may be potential reservoirs of arbekacin-resistant MRSA.

ACKNOWLEDGMENTS
We thank T. Okubo, S. Kondo, K. Kikuchi, Y. Arakawa, and A.
Wada for MRSA strains and Y. Uehara for helpful discussion.
This work was supported by a grant from the Ministry of Health, Labor, and Welfare of Japan (Molecular Analysis of Drug-Resistant Bacteria and Establishment Rapid Identification Methods, no. H12-Shinkou-19).

FOOTNOTES
* Corresponding author. Mailing address: Department of Bioactive Molecules, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: 81 3 5285 1111. Fax: 81 3 5285 1272. E-mail:
ishino{at}nih.go.jp.

Published ahead of print on 13 December 2006. 

REFERENCES
1 - Goh, S.-H., S. K. Byrne, J. L. Zhang, and A. W. Chow. 1992. Molecular typing of Staphylococcus aureus on the basis of coagulase gene polymorphisms. J. Clin. Microbiol. 30:1642-1645.[Abstract/Free Full Text]
2 - Hookey, J. V., J. F. Richardson, and B. D. Cookson. 1998. Molecular typing of Staphylococcus aureus based on PCR restriction fragment length polymorphism and DNA sequence analysis of the coagulase gene. J. Clin. Microbiol. 36:1083-1089.[Abstract/Free Full Text]
3 - Ida, T., R. Okamoto, C. Shimauchi, T. Okubo, A. Kuga, and M. Inoue. 2001. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J. Clin. Microbiol. 39:3115-3121.[Abstract/Free Full Text]
4 - Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39:4445-4451.[Abstract/Free Full Text]
5 - Ishino, K., J. Ishikawa, Y. Ikeda, and K. Hotta. 2004. Characterization of a bifunctional aminoglycoside-modifying enzyme with novel substrate specificity and its gene from a clinical isolate of methicillin-resistant Staphylococcus aureus with high arbekacin resistance. J. Antibiot. 57:679-686.[Medline]
6 - Kondo, S., Y. Ikeda, S. Hattori, M. Hamada, and T. Takeuchi. 1991. Susceptibility of methicillin-resistant Staphylococcus aureus to various antibiotics. Classification by aminoglycoside-modifying enzymes and antibiotics active against MRSA. Jpn. J. Antibiot. 44:1211-1215.[Medline]
7 - Piao, C., T. Karasawa, K. Totsuka, T. Uchiyama, and K. Kikuchi. 2005. Prospective surveillance of community-onset and healthcare-associated methicillin-resistant Staphylococcus aureus isolated from a university-affiliated hospital in Japan. Microbiol. Immunol. 49:959-970.[Medline]
8 - Schwarzkopf, A., and H. Karch. 1994. Genetic variation in Staphylococcus aureus coagulase genes: potential and limits for use as epidemiological marker. J. Clin. Microbiol. 32:2407-2412.[Abstract/Free Full Text]
9 - Tabata, M., M. Shimizu, M. Araake, and H. Ogawa. 2003. Relationship between arbekacin-susceptibility and aminoglycoside-resistant gene of methicillin-resistant Staphylococcus aureus (MRSA). Jpn. J. Antibiot. 56:36-43.
10 - Tsuchizaki, N., K. Ishino, F. Saito, J. Ishikawa, M. Nakajima, and K. Hotta. 2006. Trends of arbekacin-resistant MRSA strains in Japanese hospitals (1979 to 2000). J. Antibiot. 59:229-233.[Medline]
Journal of Clinical Microbiology, February 2007, p. 607-609, Vol. 45, No. 2
0095-1137/07/$08.00+0 doi:10.1128/JCM.02099-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.